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duration and amplitude), DIII (terminal S wave duration and amplitude), V5 (terminal S wave 1 duration and amplitude) and aVR (terminal R wave duration and amplitude). 2
All measurements were performed using Image J software (National Institutes of 3 Health, Bethesda, Maryland, http://rsb. info.nih.gov/ij). 4 5
Genetic analysis 6
The SCN5A gene was screened in each proband. Relatives were screened for familial 7 mutations according to the genetic status of the proband. 8
Genomic DNA was extracted from peripheral blood leukocytes using standard protocols. All 28 9 exons of SCN5A were amplified by polymerase chain reaction (PCR) utilizing intronic primers. PCR 10 products were screened for SCN5A mutations using denaturing high performance liquid 11
chromatography (dHPLC)-DNA sequencing or High Resolution Melting (HRM). The description of 12
mutations is based on cDNA reference sequence GenBank NM_198056. 13
This study was conducted according to European guidelines for clinical and genetic research. 14 Institutional ethical committees approved clinical and genetic database. Informed written consent was 15 obtained from each patient who agreed to participate in the clinical and genetic study. 16
Statistical Analysis 17
Data were analysed with the SPSS and SAS packages (SPSS Inc version 23, 0, 18 Chicago, Ill; SAS Institute Inc version 9,4, Cary, NC Multivariate logistic regression models were used to identify provider-related factors 24 associated with positive tests. 25
All tests were 2 tailed and a P value under 0.05 was considered as statistically 1
The study population consist of 672 consecutive patients from 137 families (median 3 age 40 ± 17 years). Three hundred and twenty-eight patients were male (49%). Three hundred 4 and thirty-seven patients (50%) presented a positive SCBC with an induced type 1 ECG 5 pattern. The molecule used was ajmaline in 497 (74%) and flecainide in 175 (26%) SCBC. 6 SCN5A mutation was identified in 43/136 (31%) probands and in 120/268 (45%) of their 7 relatives. Population characteristics are summarized in Table 1 . 8
Characteristics of positive SCBC 9
Among the 672 SCBC, a positive result was associated with age (41+/-16 vs 36 +/-17 10 y; p=0.004), the presence of a SCN5A mutation in the family (93 (79%) vs 27 (28%); 11 p<0.001) and the use of ajmaline (272 (54%) of positive SCBC vs 65 (37%) for flecainide; 12 p<0.001) (figure 1). 13
Patients with a positive SCBC additionally presented at baseline a longer P wave (68 ± 14 19 ms vs 62 ± 17 ms; P <0.001), PR (156 ± 31 ms vs 146 ± 27 ms; P <0.001) and QTc 15 interval (407 ± 39 ms vs 394 ± 36 ms; P <0.001) in V1 lead and a longer QRS interval (92 ± 16 19 ms vs 82 ± 16 ms; P <0.001) in DII lead. Both duration and amplitude of the terminal S 17 wave in DII, DIII and V5 leads and the terminal R wave in aVR were also associated with a 18 positive SCBC (P <0.0001). Similar results were observed at the end of the SCBC ( Table 2) . 19
In multivariate analysis, the drug used (ajmaline vs flecainide) was the best predictor 20 of a positive SCBC (OR 2.98 (1.65-4.91); P <0.0001). A significant S wave (e.g., amplitude> 21 1 mV and duration > 40 ms) in DII (OR=3.11 (2.12-4.58), P <0.0001, DIII (OR= 2.75 (1.78-22 4.25), P <0.0001) and V5 lead ), P <0.0001) or a significant terminal R 23 wave in aVR (OR= 2.22 (1.51-3.26), P <0.0001) were also associated with a positive SCBC 24
Among the 672 SCBC performed, complications occurred in 11 (1.6%) including 9 2 sustained VT, one VF and one atrial flutter. Four of these patients required external DC 3
shock. There were neither high-grade conduction disorders, nor deaths caused by SCBC. 4
Three families presented complications during SCBC in several (2 to 3) family members. 5 SCN5A variant segregating with the phenotype has been identified in those three families. 6
The (c.2254G>A) has been previously described as a mutation.
12,13 The two others 7 (c.2998C>T and c.5417_5420del) are frameshift or non-sense variant whose one has been 8 previously described 14 . 9
The main clinical risk factor for complications was familial history of complicated 10 SCBC (OR = 41 [10; 203] ; P <0.0001) and younger age (median age 21 ± 18 v 42 ±16 years; 11 P =0.04). There was a non-significant trend to a higher risk of complications with the use of 12 ajmaline (11 complications /497 SCBCs for ajmaline vs 0/175 for flecainide; P =0.07). 13
Complications were also associated with a longer P wave (114 ± 16 vs 92 ± 18 ms; P 14 =0.004) and PR interval (192 ± 27 ms vs 162 ± 28 ms; P =0.004) at baseline. The terminal S 15 wave in lead DII (65 ± 25 ms vs 32 ± 23 ms; P <0.0001), DIII (57 ± 30 ms vs 25 ± 27 ms; P 16 <0.0001) and the terminal R wave in aVR (50 ± 16 ms vs 30 ± 21 ms; P <0.0001) duration 17 were also significantly larger in complicated SCBC. 18
QRS duration during SCBC was not associated with complications (133 ± 21 ms vs 19
134 ± 35 ms; P =0.9) (figure 2). However, among the 11 patients with complications, 6 20 (54%) does not achieve the drug challenge leading to decrease the median dose of sodium 21 channel blocker to 0.25 (0.2-0.5) mg/kg. Additionally, median QRS enlargement during the 22 test trend to be higher in the presence of complication (133%+-22 vs 127% +-31; p=0.06). 23
Fifty-seven percent of patient with positive tests and 39% of patients with negative tests had a 24 QRS enlargement higher than 30% in DII lead. 25
After a median follow-up of 106 [54-143] months, 11 patients (73% male; mean age: 2 38 ± 18 y) experienced life-threatening arrhythmia including 1 SCD, 1 aborted SCD and 9 3 appropriate shocks. These nine patients who experienced appropriated shock had positive 4
SCBC is the corner stone of Brs screening as it allows unmasking the diagnostic 2 Brugada ECG pattern particulary during familial screening. Considering the doubt about 3 SCBC safety and a low risk of arrhythmia in asymptomatic relatives with undiagnosed 4 baseline ECG, some argues this familial screening should be restricted 15 . However, diagnosis 5 in such patients can allow to introduce general lifestyle changes preventing arrhythmia 6 occurrence and to carry on with the familial screening in descendant, which can present a 7 higher risk of arrhythmia 16 . 8 Overall, our study demonstrated that SCBC is safe. The complication rate was only 9
1.6%, confirming the safety of this test when performed in an appropriate environment 8 . We 10 identified that family history of adverse events during the SCBC represents the stronger risk 11 factor for the occurrence of arrhythmia during the test. Indeed, 63% of the complications 12 (7/11) in our study involved 3 out of the 137 families studied. This data suggests that these 13 families have an increased susceptibility to the occurrence of complications probably due to a 14 particular genotype. Of note, a SCN5A mutation was found in these three families. Those 15 families presented with segregation of a SCN5A variant, whose one has been previously 16 described as a mutation 12,13 and the two others are frameshift or non sense mutation that may 17 lead to a decreased Na current and an increased effect of sodium channel blockers 14 . 18
However, the phenotype we observed has never been described in previous studies of patients 19 carrying the same mutation. 20
Patients with complications were also younger (median age: 21 ± 18 years). As 21 recently described by Conte 17 , the risk of complications is increased in children. In our study, 22 8 patients were under 16 years of age at the time of the SCBC and 3 (37.5%) presented a 23 complication during the test that is from far higher than in the rest of the population. There is 24 currently no clear explanation for this increased rate. In children, because of the absence of 25 M A N U S C R I P T
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fibrosis of the his bundle and its branches, there is a good security factor allowing a normal or 1 subnormal propagation of the cardiac influx even in case of decrease of the sodium current, 2 such with SCN5A mutation 18 . This may explain the rarity of the Brugada syndrome in 3 children 19, 20 . However, although Brs is relatively rare in children, it appears to be associated 4 with an increased rate of conduction disturbance at baseline 17, [19] [20] [21] . Then, SCN5A mutation 5 are from far more frequent in children with Brs than in adult 20 that confirm the importance of 6 a decreased sodium current to unmask the Brugada syndrome in children. This suggests that 7 the presence of conduction abnormalities (even minor) in children is in fact in relation with a 8 strong decrease of the ability of the cardiac influx to propagate into the conduction tissue. In 9 this situation, the addition of a sodium cardiac blocker could lead to a dramatic decrease of 10 the conduction and then to severe complications. This is in line with the fact that, in our study, 11 conduction disturbance at baseline is associated with complication occurrence. Notably, the 12 presence of a terminal S wave in DII, DIII and V5 or a terminal R wave in aVR, which can 13 represent enhanced conduction delay in the right ventricular outflow tract (RVOT) 22 , depict 14 patients at higher risk of complications during the test. 15 QRS enlargement during the test was previously related to a high risk of 16 complications 6 . As previously suggested by Batchvarov 7 , our study demonstrates that a 17 significant number of patients have an enlargement of the QRS over 30% before the end of 18 the test. In fact, 57% of patient with positive tests had a QRS enlargement higher than 30% 19 meaning that if we had strictly followed the guidelines, the sensitivity of the test will have 20 been dramatically decreased while the risk of complications in this situation appears to be 21 low. Then, our results suggest changing the guidelines, as stopping prematurely the test for 22 QRS enlargement of more than 30% will lead to an unacceptable number of patients 23 undiagnosed without significantly decreasing the risk of complications. However, as 24 demonstrated in several case reports 9, 23, 24 , management of such QRS enlargement could 25 M A N U S C R I P T
require specific attention. Indeed, in the complicated group, the QRS enlargement appears to 1 be faster despite a lower dosage of SCN5A channel blockers. Although we are not able to 2 identify stopping criteria according to the QRS enlargement kinetic, a fast enlargement during 3 the test may sensitize the physician about the risk of complication. As a consequence, SCBC 4
should always be performed in experienced center. 5 6
ECG criteria to detect patients at high risk of a positive test 7
We demonstrated that significant S wave in inferolateral leads and terminal R wave in 8 aVR lead at baseline were associated with a positive response to SCBC. These results confirm 9 previous study 25 and can help to select patients who need the test to confirm the diagnosis of 10 BrS. It also provides interesting findings in BrS pathogenesis. The third vector of cardiac 11 depolarization, generating both such wave exhibits the depolarization of basal myocardium 12 and in particular, the right ventricular outflow tract (RVOT) 22, 26 . Baseline conduction 13 disturbances, especially axial deviation with prominent S wave in inferior or lateral leads, 14 highlight the role of conduction delay in the RVOT 27, 28 . This was recently emphasized by 15
Calò who suggests the prognostic value of RVOT conduction delay using S wave in DI lead 22 . 16
Our results reinforce the importance of conduction disturbance in the RVOT that appear to be 17 essential both in the diagnosis and prognosis of BS patients. 18
Study limitations: 19
This study was a retrospective and multicentric study. Then, SCBC procedures are different 20 with particular differences in the administration of drugs (continuous intravenous or bolus 21 injection). However identical diagnostic performances have been demonstrated on suspected 22
Brugada electrocardiograms 29 . 23 M A N U S C R I P T
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13
Conclusion 1
We demonstrated that SCBC appears to be safe. The risk of complication is 2 considerably increased in patients with a familial history of complicated SCBC and in very 3 young patients. Specific ECG markers should also be used to detect patients at higher risk. 4
Notably, a fast enlargement during the test may sensitize the physician about the risk of 5
complication. 6
Although conduction disturbance appears efficient to predict a positive test, QRS 7 enlargement is not significantly related to complications in our study. It should not be used to 8 prematurely stop the test unless leading to false negative results. However, S amplitude (mV) DII 1.72 ± 1.7 1.2 ±1.5 < 0.0001 3 ± 2.2 2.2 ± 2.8 < 0.0001 DIII 2 ± 2.8 1.3 ± 2.5 < 0.0001 2.5 ± 2.9 1.8 ± 2.6 < 0.0001 V5 3.5 ± 3 2.6 ± 2.9 < 0.0001 7 ± 4.8 5 ± 3.5 0.0003 R amplitude (mV) aVR 1.5 ± 2.1 1.1 ± 1.78 < 0.0001 2.4 ± 1.5 1.9 ± 2.6 < 0. The test (ajmaline 1mg/kg over 10 min) was performed in an asymptomatic 18 yo woman 4 after the identification of a symptomatic BrS in her father. 5
Please note the S wave in DII and DIII on baseline ECG and the QRS fragmentation in 6 precordial leads. 7
Measurement performed in 3 consecutive beats reveal a significant increased in the PR 8 interval (from 268 ms to 304 ms), the QRS interval (from 81 ms to 143 ms) and the QT 9 interval (from 381 ms to 420 ms) during the test. All ECG was performed with a 25 mm/s 10 speed and a 10 mm/mV amplitude. No complication occurred during the test. 
